Summit Incurs In-Line Q4 Loss, Inks Collaboration Deal With PfizerZacks Investment Research • 02/25/25
Akeso Highlights Collaboration Between Its Partner Summit Therapeutics and Pfizer to Explore Ivonescimab in Combination with Pfizer's ADCsPRNewsWire • 02/25/25
Summit Therapeutics: Mid-2025 NSCLC Data Could Further Entrench Ivonescimab ProgramSeeking Alpha • 02/24/25
Summit Therapeutics Reports Financial Results and Operational Progress for the Fourth Quarter and Twelve Months Ended December 31, 2024Business Wire • 02/24/25
Summit Therapeutics Announces Clinical Trial Collaboration with Pfizer to Evaluate Ivonescimab in Combination with Pfizer Antibody Drug Conjugates (ADCs)Business Wire • 02/24/25
Summit Therapeutics to Host Fourth Quarter and Full Year 2024 Financial Results & Operational Progress Call on February 24, 2025Business Wire • 02/18/25
Up More Than 500% in 12 Months, Is It Too Late to Buy Summit Therapeutics Stock?The Motley Fool • 01/30/25
3 Unstoppable Stocks to Buy That Wall Street Thinks Will Soar More Than 35%The Motley Fool • 01/23/25
Summit Therapeutics: Data Signals A Potential Paradigm Shift In NSCLC (Rating Upgrade)Seeking Alpha • 01/18/25
Summit Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare ConferenceBusiness Wire • 01/07/25
2 Soaring Stocks That Could Climb 68% to 166% Higher in 2025, According to Wall StreetThe Motley Fool • 12/15/24
Investing $5,000 in Each of These 3 Stocks at the Start of 2024 Would Have Created a Portfolio Worth More Than $100,000 TodayThe Motley Fool • 12/14/24